Crude and adjusted change in mean RVSP.
| ß | Crude (95% CI) | p | ß | Adjusted* (95% CI) | p | |
|---|---|---|---|---|---|---|
| Telangiectasia score (per 10-point increase) | 10.8 | (4.5, 17.2) | 0.001 | 10.9 | (3.6, 18.3) | 0.004 |
| Age (per 10 yrs) | 4.0 | (1.8, 6.1) | < 0.001 | 2.0 | (−0.5, 4.6) | 0.12 |
| Race/ethnicity** | 0.56 | 0.55 | ||||
| Black | −2.3 | (−10, 5.5) | 3.6 | (−4.1, 11.3) | ||
| Hispanic | −18.9 | (−44.5, 6.7) | −16.1 | (−40.0, 7.8) | ||
| Asian/Pacific Islander | −5.1 | (−20.1, 9.9) | 3.1 | (−11.6, 17.7) | ||
| Mid-East/Arabian | −10.6 | (−46.7, 25.4) | −5.6 | (−39.9, 28.7) | ||
| Scleroderma subtype (diffuse vs limited) | −6.1 | (−12.1, −0.1) | 0.047 | −1.8 | (−8.6, 4.9) | 0.59 |
| Scleroderma disease duration (per 10 yrs) | 3.3 | (−0.2, 7.0) | 0.07 | −0.5 | (−4.5, 3.6) | 0.81 |
| Autoantibody status | ||||||
| Anticentromere | 5.8 | (−1.4, 12.9) | 0.11 | 4.0 | (−3.7, 11.7) | 0.31 |
| Anti-Scl 70 | −0.1 | (−7.4, 7.3) | 0.99 | 4.8 | (−2.5, 12.1) | 0.19 |
| Anti-RNP | 5.6 | (−3.9, 15.1) | 0.25 | 8.6 | (−1.0, 18.2) | 0.08 |
| Smoking history | 0.02 | 0.26 | ||||
| Former vs never | 8.7 | (2.3, 15.1) | 5.0 | (−1.7–11.7) | ||
| Current vs never | −0.6 | (−10.0, 8.7) | −1.9 | (−11.3, 7.4) |